WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

Insights from 2024 WCLC

P. Lee

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

Role of Surgery in Locally Advanced NSCLC

Memorial Sloan Kettering Cancer Center

K. Gray

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Surveillance Imaging in Solid Tumors: More Complicated Than It Appea…

ecancer

C. Booth

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

WCLC 2024 Insights: MARIPOSA - Amivantamab + Lazertinib vs. Osimerti…

Insights from 2024 WCLC

S. Gadgeel

WCLC 2024 Insights: Interstitial Lung Disease and Lung Cancer - How …

Insights from 2024 WCLC

S. Ikeda

ESMO 2024 Summary: EGFRm NSCLC Panel Discussion - MARIPOSA, PAPILLON…

ecancer

I. Gil-Bazo, M. Brandão, B. Besse, E. Felip

Pan-KRAS Inhibition: Insights Into NSCLC and Beyond

Benjamin Herzberg

Biopsies in Lung Cancer: Tumor vs. Liquid

GRACE

J. Luo

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

2024 ASCO® Annual Meeting Insights Hub

L. Raez

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

Treatment Updates in Advanced and Metastatic NSCLC - Advances in Tho…

Total Health

J. Porter

An Update on Lung Cancer Targeted Therapies: The Evolution of Person…

University of Miami Sylvester Comprehensive Cancer Center

E. Rodriguez

Overview of Lung Cancer Classification and Rare Alterations

Lung Cancer Europe (LuCE)

B. Besse

New Frontiers in Oncology: Advanced Diagnostics and Therapeutics

Springer Healthcare IME

S. Peters